Skip to main content
Cellectar Biosciences, Inc. logo

Cellectar Biosciences, Inc. — Investor Relations & Filings

Ticker · CLRB ISIN · US15117F8077 LEI · 5493000NFZCRG7BYQV93 US Manufacturing
Open in API
Filings indexed 1,033 across all filing types
Latest filing 2012-10-29 Capital/Financing Update
Country US United States of America
Listing US CLRB

About Cellectar Biosciences, Inc.

https://www.cellectar.com/

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted cancer treatments. The company's core technology is a proprietary Phospholipid Drug Conjugate (PDC) platform that selectively delivers therapeutic payloads, such as radioisotopes and cytotoxins, to cancer cells by targeting lipid rafts in their plasma membranes. This approach is designed to maximize antitumor activity while minimizing off-target effects on healthy tissue. Cellectar's lead product candidate is iopofosine I 131, a first-in-class PDC that delivers the radioisotope iodine-131. It is being developed for the treatment of hematologic malignancies and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for Waldenstrom's Macroglobulinemia.

Recent filings

Filing Released Lang Actions
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(3), which relates to securities offerings and stockholder matters. It includes information about a special meeting of stockholders where directors were re-elected and a stock incentive plan was amended. The document is not a full financial report, earnings release, or management discussion. It is primarily an announcement related to capital structure and stockholder voting results. Given the content about stockholder meeting results and stock incentive plan amendments, this fits best under Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or regulatory filing. Therefore, the classification is CAP with high confidence.
2012-10-29 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(3), which relates to securities offerings and fundraising activities. It details the sale of units consisting of common stock and warrants, and includes information about a special meeting of stockholders where stock incentive plans were amended and directors were re-elected. The content focuses on capital raising and securities issuance rather than financial results, management discussion, or regulatory compliance filings. The document length is short (2151 characters) and it is clearly a supplement to a prospectus, indicating it is a capital/financing update rather than a full report or announcement of voting results. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2012-10-29 English
CURRENT REPORT
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, titled 'Current Report.' It reports the submission of matters to a vote of security holders at a special meeting, including election results of directors and approval of an amendment to the stock incentive plan. The content focuses on voting results and corporate governance matters rather than full financial statements or detailed financial performance. The document length is 3543 characters, which is relatively short and consistent with a current report rather than a full annual or quarterly report. The key section is ITEM 5.07, which relates to submission of matters to a vote of security holders. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). Therefore, the appropriate classification is DVA with high confidence.
2012-10-26 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 95% confidence The document is titled 'Prospectus Supplement' and is filed pursuant to Rule 424(b)(3), which is a SEC rule related to prospectus supplements for securities offerings. It discusses the exercise of Class B Warrants and the proceeds from such exercises, as well as the intended use of proceeds and cash position. The document is clearly related to financing activities and capital raising. It is not an annual report, earnings release, or management discussion. It is not a regulatory filing in the sense of certifications or legal proceedings. The document is a supplement to a prospectus, which is a capital raising document. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is short (2073 characters), but it contains substantive information about financing activities, not just an announcement of a report publication, so it is not RPA or RNS.
2012-10-17 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 95% confidence The document is titled 'Prospectus Supplement' and is filed pursuant to Rule 424(b)(3), which is a SEC rule related to prospectus supplements for securities offerings. It discusses the exercise of warrants and the proceeds received, as well as the intended use of those proceeds for general corporate purposes. The document does not contain financial statements or detailed financial analysis but rather provides an update on financing activities related to share issuance and warrant exercises. The length is relatively short (2312 characters), and the content focuses on capital raising and securities issuance. Therefore, this document fits best under the category 'Capital/Financing Update' (CAP).
2012-10-17 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes the issuance and exercise of warrants, proceeds received, and cash position, which relates to financing activities. There is no detailed financial statement or comprehensive report, but rather an update on capital raising and warrant exercises. The document length is 3666 characters, which is relatively short and consistent with an 8-K filing. Given the focus on warrant issuance, exercise, and proceeds, this fits best under Capital/Financing Update (CAP).
2012-10-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.